vs

Side-by-side financial comparison of Business First Bancshares, Inc. (BFST) and BillionToOne, Inc. (BLLN). Click either name above to swap in a different company.

BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $83.1M, roughly 1.0× Business First Bancshares, Inc.). On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 7.1%). Business First Bancshares, Inc. produced more free cash flow last quarter ($92.0M vs $6.5M).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.

BFST vs BLLN — Head-to-Head

Bigger by revenue
BLLN
BLLN
1.0× larger
BLLN
$83.5M
$83.1M
BFST
Growing faster (revenue YoY)
BLLN
BLLN
+110.3% gap
BLLN
117.4%
7.1%
BFST
More free cash flow
BFST
BFST
$85.6M more FCF
BFST
$92.0M
$6.5M
BLLN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BFST
BFST
BLLN
BLLN
Revenue
$83.1M
$83.5M
Net Profit
$5.7M
Gross Margin
69.9%
Operating Margin
33.2%
11.5%
Net Margin
6.8%
Revenue YoY
7.1%
117.4%
Net Profit YoY
138.3%
EPS (diluted)
$0.71
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFST
BFST
BLLN
BLLN
Q4 25
$83.1M
Q3 25
$80.9M
$83.5M
Q2 25
$81.5M
Q1 25
$79.2M
Q4 24
$77.6M
Q3 24
$66.9M
$38.4M
Q2 24
$66.2M
Q1 24
$60.9M
Net Profit
BFST
BFST
BLLN
BLLN
Q4 25
Q3 25
$22.9M
$5.7M
Q2 25
$22.1M
Q1 25
$20.5M
Q4 24
Q3 24
$17.8M
$-14.9M
Q2 24
$17.2M
Q1 24
$13.6M
Gross Margin
BFST
BFST
BLLN
BLLN
Q4 25
Q3 25
69.9%
Q2 25
Q1 25
Q4 24
Q3 24
52.6%
Q2 24
Q1 24
Operating Margin
BFST
BFST
BLLN
BLLN
Q4 25
33.2%
Q3 25
35.7%
11.5%
Q2 25
34.4%
Q1 25
32.6%
Q4 24
27.5%
Q3 24
34.0%
-32.9%
Q2 24
32.9%
Q1 24
28.2%
Net Margin
BFST
BFST
BLLN
BLLN
Q4 25
Q3 25
28.2%
6.8%
Q2 25
27.1%
Q1 25
25.9%
Q4 24
Q3 24
26.7%
-38.8%
Q2 24
26.0%
Q1 24
22.3%
EPS (diluted)
BFST
BFST
BLLN
BLLN
Q4 25
$0.71
Q3 25
$0.73
$0.10
Q2 25
$0.70
Q1 25
$0.65
Q4 24
$0.51
Q3 24
$0.65
$-1.47
Q2 24
$0.62
Q1 24
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFST
BFST
BLLN
BLLN
Cash + ST InvestmentsLiquidity on hand
$411.2M
$195.2M
Total DebtLower is stronger
$55.0M
Stockholders' EquityBook value
$896.9M
$-239.5M
Total Assets
$8.2B
$327.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFST
BFST
BLLN
BLLN
Q4 25
$411.2M
Q3 25
$399.1M
$195.2M
Q2 25
$495.8M
Q1 25
$312.9M
Q4 24
$319.1M
Q3 24
$213.2M
Q2 24
$208.1M
Q1 24
$185.9M
Total Debt
BFST
BFST
BLLN
BLLN
Q4 25
Q3 25
$55.0M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BFST
BFST
BLLN
BLLN
Q4 25
$896.9M
Q3 25
$878.4M
$-239.5M
Q2 25
$848.4M
Q1 25
$826.3M
Q4 24
$799.5M
Q3 24
$699.5M
$-242.9M
Q2 24
$664.5M
Q1 24
$649.0M
Total Assets
BFST
BFST
BLLN
BLLN
Q4 25
$8.2B
Q3 25
$8.0B
$327.5M
Q2 25
$7.9B
Q1 25
$7.8B
Q4 24
$7.9B
Q3 24
$6.9B
Q2 24
$6.7B
Q1 24
$6.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFST
BFST
BLLN
BLLN
Operating Cash FlowLast quarter
$92.1M
$13.8M
Free Cash FlowOCF − Capex
$92.0M
$6.5M
FCF MarginFCF / Revenue
110.7%
7.7%
Capex IntensityCapex / Revenue
0.1%
8.8%
Cash ConversionOCF / Net Profit
2.42×
TTM Free Cash FlowTrailing 4 quarters
$165.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFST
BFST
BLLN
BLLN
Q4 25
$92.1M
Q3 25
$32.4M
$13.8M
Q2 25
$14.0M
Q1 25
$28.7M
Q4 24
$61.4M
Q3 24
$21.4M
Q2 24
$15.1M
Q1 24
$7.6M
Free Cash Flow
BFST
BFST
BLLN
BLLN
Q4 25
$92.0M
Q3 25
$32.1M
$6.5M
Q2 25
$13.8M
Q1 25
$27.7M
Q4 24
$59.8M
Q3 24
$21.0M
Q2 24
$14.0M
Q1 24
$7.2M
FCF Margin
BFST
BFST
BLLN
BLLN
Q4 25
110.7%
Q3 25
39.6%
7.7%
Q2 25
16.9%
Q1 25
34.9%
Q4 24
77.1%
Q3 24
31.4%
Q2 24
21.2%
Q1 24
11.8%
Capex Intensity
BFST
BFST
BLLN
BLLN
Q4 25
0.1%
Q3 25
0.4%
8.8%
Q2 25
0.3%
Q1 25
1.3%
Q4 24
2.0%
Q3 24
0.6%
Q2 24
1.6%
Q1 24
0.6%
Cash Conversion
BFST
BFST
BLLN
BLLN
Q4 25
Q3 25
1.42×
2.42×
Q2 25
0.63×
Q1 25
1.40×
Q4 24
Q3 24
1.20×
Q2 24
0.88×
Q1 24
0.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BFST
BFST

Segment breakdown not available.

BLLN
BLLN

Prenatal$74.1M89%
Oncology$8.7M10%

Related Comparisons